NASDAQ: CASI | 中文 | Contact Us

Events

Upcoming Events

August 10, 2020

CASI Pharmaceuticals To Report Second Quarter 2020 Financial Results And Host Conference Call August 10, 2020

The Company will host a conference call reviewing the second quarter highlights at 4:30 p.m. ET on Monday, August 10th, 2020.
On the call, CASI’s Chairman & CEO will provide an update on the Company’s business and upcoming milestones. The conference call can be accessed by dialing (833) 647-4459 (U.S.), (800) 870-0181 (China), (400) 682-8629 (China, domestic), 800933597 (Hong Kong) to listen to the live conference call. The conference ID number for the live call is 5223239. Participants dialing in via International Toll-Free Service (ITFS) numbers will be required to provide the following passcode to join the conference call: 8336474459, 6025859887.

Archived Events

June 16, 2020

Annual Meeting

Meeting materials and proxy statement available at

Annual Meeting Download

https://www.casipharmaceuticals.com/investor-relations/annual-stockholders-meeting-notice-and-proxy/

June 4, 2020, 4:00 p.m. ET

Jefferies 2020 Healthcare Conference

Dr. Wei-Wu He, Chairman & CEO will present an overview of the company and provide a business update at the Jefferies 2020 Healthcare Conference on Thursday, June 4, 2020, at 4:00 p.m. ET. The conference will be held in a virtual meeting format.

Meeting link

May 11, 2020

Conference Call - First Quarter Highlights

The Company will host a conference call reviewing the first quarter highlights at 4:30 p.m. ET on Monday, May 11, 2020. On the call, CASI’s Chairman & CEO will provide an update on the Company’s business and upcoming milestones. The conference call can be accessed by dialing (833) 647-4459 (U.S.), 8008700181 (China), 58086567 (Hong Kong) to listen to the live conference call. The conference ID number for the live call is 8716619.

Apr 07, 2020

CASI Pharmaceuticals To Present at 2020 Solebury Trout Virtual Investor Conference

Dr. Wei-Wu He, Chairman & CEO will present an overview of the company and provide a business
update at the Solebury Trout Virtual Global Healthcare Series. During the 25-minute presentation,
participants will be able to submit questions electronically with answers provided by the discretion
of the company on an individual basis afterwards. Details are as follows:

Date/Time:
Tuesday, April 7, at 11:00a.m./p.m. EDT
To access the archived presentation, please login at:

Archive

https://78449.themediaframe.com/dataconf/productusers/solebury/mediaframe/36850/indexl.html

Mar 16, 2020

Full Year 2019 Financial Results Conference Call

The Company will host a conference call reviewing the full year 2019 highlights at 4:30 p.m. ET on
Monday, March 16, 2020. On the call, CASI’s Chairman & CEO will provide an update on the
Company’s business and upcoming milestones. The conference call will be conducted in English, and
can be accessed by dialing (833) 647-4459 (U.S.), 8008700181 (China), 58086567 (Hong Kong) to listen
to the live conference call. The conference ID number for the live call is 5894813.

Sep 10, 2019

Key Opinion Leader (KOL) Symposium

On September 10th in New York City, CASI Pharmaceuticals hosted a key opinion leader (KOL) symposium
addressing innovations in cancer immunotherapy and recent regulatory reforms impacting the China
biopharmaceutical market. The meeting featured presentations by Nobel Prize winning immunologist
James P. Allison, Ph.D. and the former head of Chinese National Medical Product Administration
(NMPA), the Chinese FDA, Dr. Ruyi He, M.D. In addition to the presentations there was a panel and
interactive Q&A session moderated by Brad Loncar, a renowned blogger and pundit on the China
pharmaceutical space. Participating in the panel were KOL speakers Dr. James Allison and Dr. Ruyi He
along with CASI CEO Wei-Wu He, Ph.D.; Lynda Chin, M.D. and President and CEO of Apricity Health LLC;
Lulu Lv, M.D., Ph.D. and CEO of Juventas Cell Therapy; and Jinzi Wu, Ph.D. and Chairman and CEO of
Ascletis. Among many subjects addressed on the panel, the group discussed where they saw the biotech
industry going in five years and more specifically, where would China’s biopharma industry be in
five years.
Event Video

Sep 10, 2019

NASDAQ Bell Ringing

On September 10th, at the NASDAQ MarketSite in Times Square, CASI Pharmaceuticals had the honor of
ringing the closing bell for the NASDAQ exchange. CASI CEO Wei-Wu He did the honors with the rest of
the CASI team in attendance.

About Us

CASI is a U.S. NASDAQ-listed biopharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China, through which substantially all of our operations are conducted.

Learn More